Vical signs Vaxfectin adjuvant licensing deal with Cyvax

Vaxfectin adjuvant has demonstrated to considerably increase the antibody and T-cell immune responses against antigens expressed from DNA vaccines in multiple animal models.

The adjuvant will be used by Cyvax in malaria vaccine development. Financial terms of the deal were kept confidential.

Vical president and chief executive officer Vijay Samant said Vaxfectin has a range of potential applications.

"After conducting a significant body of pre-clinical work, Cyvax elected to move forward with Vical’s Vaxfectin due to the robust enhancement in efficacy we observed with that adjuvant," Samant added.

"The Vaxfectin adjuvant also offers comparative advantages across a number of other important domains including safety, tolerability, and commercial scalability."